Vigeo debuts to reprogram tumor microenvironment

Vigeo emerged from stealth Friday with $27.5 million from Morningside Venture Capital and a cancer candidate already in the clinic.

Vigeo Therapeutics Inc. (Cambridge, Mass.) is developing a pipeline of peptides, fusion proteins and antibodies that target genetically normal cells within the tumor microenvironment

Read the full 434 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE